Lexaria Receives Independent Review Board Approval To Begin Human Pilot Study #3 Investigating A DehydraTECH-Processed Version Of The Dual Action GLP-1 + GIP Tirzepatide In An Oral Dose Format
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience Corp. has received approval to begin a human pilot study on a DehydraTECH-processed oral version of tirzepatide, a drug currently only available via injection. The study aims to evaluate absorption rates and blood sugar control, with results expected by late November.
September 27, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience has received approval for a human pilot study on an oral version of tirzepatide using its DehydraTECH technology. This could potentially lead to a new product offering if successful.
The approval for the study is a significant step for Lexaria, as it explores a new oral delivery method for tirzepatide, which could expand its product offerings and market reach. Positive results could lead to increased investor interest and potential partnerships.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Lexaria Bioscience's warrant holders may see value increase if the pilot study on oral tirzepatide is successful, potentially leading to new product developments.
The success of the study could enhance the value of Lexaria's warrants (LEXXW) by increasing the company's market potential and product offerings, which may lead to higher stock prices.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80